Cardiol Therapeutics (CRDL) to Announce Earnings on Thursday

Cardiol Therapeutics (NASDAQ:CRDL) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Cardiol Therapeutics to announce earnings of ($0.09) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). On average, analysts expect Cardiol Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Cardiol Therapeutics Price Performance

Shares of Cardiol Therapeutics stock opened at $1.47 on Tuesday. The stock has a market cap of $170.36 million, a PE ratio of -5.25 and a beta of 0.72. The firm has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.17. Cardiol Therapeutics has a 1 year low of $0.88 and a 1 year high of $1.71.

Hedge Funds Weigh In On Cardiol Therapeutics

Large investors have recently bought and sold shares of the business. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Cardiol Therapeutics in the 4th quarter valued at about $31,000. Simplex Trading LLC raised its holdings in Cardiol Therapeutics by 96.9% during the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after purchasing an additional 15,842 shares during the last quarter. Bank of America Corp DE boosted its position in Cardiol Therapeutics by 136.2% during the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares in the last quarter. Susquehanna International Group LLP boosted its position in Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after purchasing an additional 73,375 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Cardiol Therapeutics in the third quarter valued at $154,000. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CRDL shares. HC Wainwright reaffirmed a “buy” rating on shares of Cardiol Therapeutics in a report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Cardiol Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Hold” and an average price target of $8.50.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.